ArticleCureus2025
Central Nervous System Involvement in Splenic Marginal Zone Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marginal zone B-cell lymphoma (MZL) represents a heterogeneous group of indolent non-Hodgkin lymphomas (NHL) originating from the marginal zone of B cells in lymphoid tissues. Typically, MZL is classified as nodal, extranodal, and MZL with splenic involvement. Central nervous system (CNS) involvement is rare, whether it presents as a primary dural lymphoma or as a consequence of secondary CNS involvement. CNS involvement of MZL presents with non-specific symptoms such as headaches, focal neurological deficits, cognitive impairment, and seizures in the setting of mass effect. It is essential to consider new CNS infiltration as a possibility in patients with hematological malignancies who exhibit new neurologic symptoms. Herein, we present a case of a patient with a ventriculoperitoneal shunt and recently diagnosed with splenic MZL who presented with status epilepticus and was subsequently diagnosed with secondary CNS involvement, highlighting its associated diagnostic and therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.